Tirzepatide Latest Research: New Indications, Trials & What’s Coming

Introduction

The original tirzepatide trials targeted type 2 diabetes (SURPASS program) and obesity (SURMOUNT program). Since 2023, the evidence base has expanded into obstructive sleep apnea (SURMOUNT-OSA), heart failure with preserved ejection fraction (SUMMIT), liver disease (SYNERGY-NASH), and ongoing cardiovascular outcomes work (SURPASS-CVOT). The drug went from a glucose and weight medication to a broader metabolic platform.

The pipeline is also active. Higher-dose oral tirzepatide formulations, combination drugs, and longer-acting variants are in development. Real-world data from large clinic databases continue to fill in the safety profile and identify patient subgroups that respond best.

This article walks through the major recent trials, what they show, and what’s coming next. It also covers the controversies around anesthesia complications, suicidality signals, and the limits of current evidence relative to semaglutide.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Did SURMOUNT-1 Establish?

SURMOUNT-1 (Jastreboff et al. 2022, NEJM) was the key weight loss trial for tirzepatide. The trial enrolled 2,539 adults with obesity (BMI 30+) or overweight with comorbidities (BMI 27 to 30) without diabetes. Patients were randomized to tirzepatide 5, 10, 15 mg or placebo for 72 weeks.

Quick Answer: SURMOUNT-OSA (Malhotra et al. 2024, NEJM): first FDA-approved drug for OSA in obesity

Mean weight loss outcomes at week 72:

• Tirzepatide 5 mg: 15% body weight
• Tirzepatide 10 mg: 19.5% body weight
• Tirzepatide 15 mg: 20.9% body weight
• Placebo: 3.1% body weight

About 91% of patients on tirzepatide 15 mg achieved 5% or more weight loss. About 57% achieved 20% or more. These numbers established tirzepatide as the most effective obesity pharmacotherapy in modern medicine, exceeding semaglutide’s STEP 1 results (14.9% on 2.4 mg).

What Did SURMOUNT-OSA Show?

SURMOUNT-OSA (Malhotra et al. 2024, NEJM) studied tirzepatide in 469 adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide 15 mg reduced the apnea-hypopnea index (AHI) by 27 to 30 events per hour from baseline, compared to a reduction of 5 to 6 events per hour on placebo.

About half of patients on tirzepatide achieved disease remission or progression to mild OSA. The FDA approved tirzepatide for obstructive sleep apnea in adults with obesity in December 2024, making it the first FDA-approved pharmacologic treatment for OSA.

The OSA approval is notable because OSA has historically been treated with CPAP devices and weight loss. A pharmacologic option creates new pathways for patients who can’t tolerate CPAP. Medicare covers tirzepatide for the OSA indication, which created a new coverage route for many patients previously excluded from weight loss drug coverage.

What Did SUMMIT Show for Heart Failure?

SUMMIT (Packer et al. 2024, NEJM) enrolled 731 patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Tirzepatide 15 mg weekly improved the Kansas City Cardiomyopathy Questionnaire symptom score by 6.9 points more than placebo and reduced the composite endpoint of cardiovascular death or worsening heart failure.

Six-minute walk distance improved by 18 to 25 meters more than placebo. Inflammatory markers (high-sensitivity C-reactive protein) dropped. The findings paralleled and confirmed STEP-HFpEF for semaglutide in the same patient population.

Tirzepatide isn’t currently FDA-approved for HFpEF specifically, but SUMMIT changed how cardiologists approach this condition. GLP-1 and dual agonist drugs are now in HFpEF treatment algorithms alongside SGLT2 inhibitors.

What’s the Status of SURPASS-CVOT?

SURPASS-CVOT is the cardiovascular outcomes trial for tirzepatide, comparing it to dulaglutide (a GLP-1 monotherapy with established CV benefit) in 13,000+ patients with type 2 diabetes and atherosclerotic cardiovascular disease. The trial is event-driven and results are expected in 2026 or 2027.

The trial design tests non-inferiority of tirzepatide vs dulaglutide for the primary cardiovascular composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke). If non-inferiority is established, secondary analyses can test superiority.

A positive SURPASS-CVOT outcome would extend the tirzepatide label to cardiovascular risk reduction, similar to what SELECT did for semaglutide. This would significantly expand coverage and use in patients with established cardiovascular disease.

What Did SYNERGY-NASH Find for Liver Disease?

SYNERGY-NASH was the phase 2 trial of tirzepatide in patients with NASH (now called MASH) with fibrosis. Tirzepatide produced histologic NASH resolution in 51 to 62% of patients at 52 weeks vs 10% on placebo. Fibrosis improvement was more modest but still significant.

Results were broadly similar to semaglutide phase 2 data (Newsome et al. 2021, NEJM showed 59% resolution on semaglutide vs 17% placebo) and confirmed the GLP-1 class as effective for MASH.

A phase 3 MASH program for tirzepatide is ongoing. Results are expected in 2027 or 2028. If positive, tirzepatide would join semaglutide and resmetirom as treatment options for MASH.

What’s the Kidney Disease Evidence?

Tirzepatide doesn’t have a dedicated kidney outcomes trial parallel to FLOW for semaglutide. Subgroup analyses from SURPASS trials suggest favorable kidney trends (reduced albuminuria, stable eGFR), but the strength of evidence is much lower than semaglutide’s FLOW data.

For diabetic patients with CKD, semaglutide currently has the clearer kidney indication based on FLOW (24% reduction in kidney/CV death). Tirzepatide may catch up as more data accumulate, but the trial would need to be designed and completed.

The mechanism would presumably parallel semaglutide’s renal effects through GLP-1 receptors on renal tubular cells and reduced inflammation. Whether the GIP component adds direct renal benefit is unknown.

What About Diabetes Outcomes?

SURPASS-1, 2, 3, 4, and 5 established tirzepatide as a highly effective diabetes medication. HbA1c reductions of 1.7 to 2.4 percentage points were larger than nearly any other diabetes drug class.

SURPASS-2 (Frias et al. 2021, NEJM) compared tirzepatide vs semaglutide 1 mg in type 2 diabetes. Tirzepatide showed larger HbA1c reduction (2.3% vs 1.9% on highest dose) and larger weight loss (11.2 kg vs 5.7 kg) at 40 weeks. The trial established the dual GIP/GLP-1 advantage over pure GLP-1 monotherapy.

SURPASS-5 added tirzepatide to insulin glargine in poorly controlled type 2 diabetes. Tirzepatide reduced HbA1c by 2.1 to 2.4 percentage points and produced significant weight loss compared to insulin alone.

What’s the Addiction and Neurodegenerative Research Showing?

Observational data on tirzepatide and addiction are limited. The mechanistic basis (reduced reward signaling through both GIP and GLP-1 receptors) suggests potential effects, but the trial-level evidence is much earlier than for semaglutide.

Phase 2 trials of tirzepatide in alcohol use disorder are in planning. The dual receptor mechanism might offer advantages over pure GLP-1 in conditions where reward and metabolic effects intersect.

Neurodegenerative disease research is even earlier for tirzepatide. The GIP receptor signaling has theoretical relevance to brain function but the clinical translation is unstudied. Phase 2 trials in early Parkinson’s are in early planning.

What’s the SURMOUNT-MMO Trial?

SURMOUNT-MMO is the morbidity and mortality outcomes trial for tirzepatide in obesity without diabetes. The trial enrolled 15,000+ patients with BMI 27+ and established cardiovascular disease or multiple CV risk factors. Results are expected in 2027.

If positive, SURMOUNT-MMO would extend tirzepatide’s label to cardiovascular risk reduction in obesity (paralleling what SELECT did for semaglutide). This would significantly broaden the patient population for tirzepatide.

The trial design tests reduction in major adverse cardiovascular events as the primary endpoint. The trial is also tracking heart failure events, kidney outcomes, and all-cause mortality.

What’s Coming in the Pipeline?

Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors. Phase 2 obesity data showed 24% weight loss at 48 weeks on 12 mg, the largest weight loss seen with any single agent. Phase 3 trials are ongoing.

The glucagon agonism component is the new mechanism. Glucagon increases energy expenditure and may produce additional weight loss beyond what GLP-1/GIP alone achieves. Safety implications of glucagon agonism (potential blood sugar effects) are being monitored in trials.

Other late-stage GLP-1 class drugs include mazdutide (GLP-1/glucagon dual), survodutide (GLP-1/glucagon dual), and several others. The field is moving toward multi-receptor agonists for greater efficacy.

Key Takeaway: SURPASS-CVOT: cardiovascular outcomes trial, results expected 2026-2027

What About Oral Tirzepatide?

Oral tirzepatide formulations are in earlier development than oral semaglutide. The peptide is harder to absorb orally than semaglutide, and absorption enhancers are needed to achieve clinically useful bioavailability.

Phase 1 and 2 trials of oral tirzepatide are ongoing. If successful, oral tirzepatide could expand the patient population by capturing patients who refuse injections. The injection form will likely remain the dominant formulation for the foreseeable future.

What About Real-world Long-term Data?

Large database studies through 2025 have followed several hundred thousand tirzepatide users for up to 4 years. Key findings:

• No emerging long-term safety signals beyond those already known
• Cardiovascular trends favorable (full outcomes data awaiting SURPASS-CVOT)
• Discontinuation rates of about 30 to 40% within first year
• About half of weight regain within 12 months of discontinuation
• Patients who stay on the drug 3+ years tend to maintain their loss

The 30 to 40% first-year discontinuation rate is a real-world concern shared with semaglutide. Cost, side effects, and insurance barriers each contribute.

What’s the Anesthesia Concern?

In 2023, the American Society of Anesthesiologists issued guidance recommending holding GLP-1 drugs including tirzepatide for at least one week before elective surgery due to delayed gastric emptying and aspiration risk.

A 2024 prospective study (Sherwin et al., Anesthesiology) found 56% of GLP-1 patients had retained gastric contents after standard 8-hour fasting vs 8% of controls. Subsequent guidance clarified specific holding periods.

For emergency surgery, anesthesia teams treat GLP-1 patients as full-stomach regardless of fasting time, using rapid sequence induction. The risk is real but manageable with appropriate planning.

What’s the Suicidality and Mental Health Signal?

The European Medicines Agency investigated suicidal ideation reports for GLP-1 drugs in 2023. Subsequent large-scale analyses, including for tirzepatide specifically, did not find an excess of suicidal ideation compared to other weight loss interventions or matched controls.

The current FDA labeling carries general mental health monitoring guidance but no specific suicidality warning beyond standard psychiatric medication monitoring. Patients with prior suicide attempts or active depression should be monitored closely on any chronic medication.

Some patients report mood improvements during tirzepatide treatment, attributed to weight loss benefits and improved metabolic health. Others report worsened mood, particularly during the active loss phase. Individual response varies.

How Does the Evidence Compare to Semaglutide?

Semaglutide has more outcomes data because it’s been on the market longer and has completed more cardiovascular and kidney outcomes trials. SELECT, FLOW, STEP-HFpEF, and SUSTAIN-6 form a deep evidence base.

Tirzepatide has stronger weight loss efficacy (20.9% vs 14.9% in key trials) and a stronger OSA indication. The cardiovascular and kidney evidence base is catching up but lags semaglutide as of 2026.

Clinical practice often uses both drugs interchangeably for weight loss, with the choice driven by patient factors, insurance coverage, tolerability, and clinician preference. As outcomes data mature for tirzepatide, the indication-based differentiation may shift.

What About the Bone Health and Sarcopenia Research?

Concerns about bone density and lean mass loss on GLP-1 drugs have prompted studies. A 2024 DEXA substudy from SURMOUNT-1 found about 25% of total weight loss was lean tissue without specific intervention. Resistance training reduced this proportion to under 15%.

Bone mineral density changes on tirzepatide are modest. The clinical relevance for fracture risk in younger adults is unclear. Older adults with osteoporosis may need monitoring during significant weight loss to ensure bone health doesn’t deteriorate.

Adequate protein intake (1.0 to 1.2 g/kg/day) combined with resistance training 2 to 3 times weekly is the standard recommendation for preserving lean mass. Specific protein supplementation or branched-chain amino acid use hasn’t shown added benefit beyond adequate total protein.

What’s the Research on Weight Maintenance After Loss?

SURMOUNT-4 (Aronne et al. 2024, JAMA) randomized patients who had achieved weight loss on tirzepatide to continue or switch to placebo for 88 weeks. Patients who continued tirzepatide maintained 25.3% loss from baseline. Patients who switched to placebo regained 14% of their initial weight loss over the trial period.

This was the first dedicated maintenance trial for a GLP-1 class drug. The results parallel STEP 4 for semaglutide and reinforce the framing of obesity drugs as chronic therapy rather than short-term treatment.

Lower maintenance dosing studies are needed to determine whether 5 or 7.5 mg tirzepatide can sustain weight loss as well as 10 or 15 mg. Observational data suggest lower doses can hold most of the loss for many patients, but randomized data are pending.

What’s the Gut Microbiome Research Showing?

Several studies have examined gut microbiome changes on tirzepatide and semaglutide. Beneficial shifts in microbial diversity, increased Akkermansia muciniphila, and other favorable patterns have been documented. The clinical implications are uncertain.

Whether microbiome changes mediate part of the drug’s clinical effects or are downstream of weight loss is unclear. Trials of microbiome interventions combined with GLP-1 drugs are in early stages.

The findings have prompted interest in probiotic and prebiotic combinations with tirzepatide. No specific microbiome intervention has yet been shown to improve clinical outcomes on tirzepatide, but the area is active.

Bottom line: Retatrutide (triple agonist) showing 24% weight loss in phase 2

FAQ

When Will Tirzepatide Get a Cardiovascular Indication?

SURPASS-CVOT and SURMOUNT-MMO are the relevant trials. Results are expected 2026-2027. If positive, FDA approval for cardiovascular risk reduction would follow within 12 to 18 months.

Will Retatrutide Replace Tirzepatide?

Possibly for some patients. Retatrutide’s larger weight loss in phase 2 (24% vs tirzepatide’s 20.9%) is impressive, but the glucagon agonism component adds safety considerations that need full evaluation in phase 3.

Is Oral Tirzepatide Coming Soon?

Earlier in development than oral semaglutide. No specific timeline for approval. Phase 1 and 2 trials are ongoing.

How Does the Research Apply to Compounded Tirzepatide?

The active molecule in compounded tirzepatide is identical to brand. The mechanistic and outcomes findings from research apply directly. The regulatory pathway is different, which is why compounded is sold under personalized prescription rather than FDA-approved indication.

Will Newer Drugs Replace Tirzepatide?

Possibly for some patients. Retatrutide and other triple agonists may produce larger weight loss than tirzepatide. Whether the newer drugs offer better cardiovascular or kidney outcomes is unknown until their outcomes trials read out. Tirzepatide will likely remain a major drug for years to come.

What About Pediatric Long-term Data?

Pediatric data on tirzepatide are limited. SURMOUNT-PED is the ongoing trial in adolescents. Long-term safety and developmental outcomes in adolescents are being tracked through ongoing registry studies.

How Strong Is the Cardiovascular Evidence Right Now?

Indirect evidence (favorable blood pressure, lipid, and inflammatory marker trends) plus the SUMMIT heart failure data suggest tirzepatide should have cardiovascular benefit. Direct outcomes trial data are pending. For now, semaglutide has the stronger formal CV evidence base.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.